Table 2 Summary of on-treatment AEs of special interest
Special interest AE group | Number (%) of patients | ||
|---|---|---|---|
UMEC/VI | UMEC | Placebo | |
125/25 mcg | 125 mcg | ||
(n = 226) | (n = 227) | (n = 109) | |
Cardiovascular | 34 (15) | 49 (22) | 25 (23) |
Pneumonia | 5 (2) | 11 (5) | 2 (2) |
Anticholinergic syndrome | 5 (2) | 5 (2) | 2 (2) |
Effects on glucose | 8 (4) | 1 (<1) | 0 |
Ocular effects | 1 (<1) | 1 (<1) | 1 (<1) |
Gallbladder disorders | 0 | 2 (<1) | 0 |
Effects on potassium | 0 | 1 (<1) | 0 |
Tremor | 0 | 0 | 0 |
Urinary retention | 0 | 0 | 0 |
Intestinal obstruction | 0 | 0 | 0 |